Evidence map›Paper›PMID 29791289›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy.

Daniel J Boffa, Andrzej S Kosinski, Anthony P Furnary, Sunghee Kim, Mark W Onaitis, Betty C Tong, Patricia A Cowper, Jessica R Hoag, Jeffrey P Jacobs, Cameron D Wright and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Minimally invasiveTranslational lung cancer research · 2025
    Article
  12. Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Daniel J BoffaDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Andrzej S KosinskiDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Anthony P FurnaryDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Sunghee KimDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Mark W OnaitisDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Betty C TongDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Patricia A CowperDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Jessica R HoagDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Jeffrey P JacobsDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Cameron D WrightDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Joe B PutnamDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Felix G FernandezDaniel J. Boffa and Jessica R. Hoag, Yale School of Medicine, New Haven, CT; Andrzej S. Kosinski, Sunghee Kim, and Patricia A. Cowper, Duke Clinical Research Institute; Betty C. Tong, Duke University School of Medicine, Durham, NC; Anthony P. Furnary, Starr-Wood Cardiac Group, Portland, OR; Mark W. Onaitis, University of California, San Diego School of Medicine, San Diego, CA; Jeffrey P. Jacobs, Johns Hopkins All Children's Heart Institute; Saint Petersburg; Joe B. Putnam Jr, Baptist MD Anderson Cancer Center, Jacksonville, FL; Cameron D. Wright, Massachusetts General Hospital, Boston, MA; and Felix G. Fernandez, Emory University, Atlanta, GA.
Clinical Research Institute · US

Funding

National Longitudinal Outcomes Following Surgical Therapy for Lung CancerR01HS022279 · AHRQ · SOCIETY OF THORACIC SURGEONS · PI FERNANDEZ, FELIX GABRIEL · 2014 to 2017
$986k
AHRQ HHS R01 HS022279
6 · The paper itself

Abstract

Purpose The prevalence of minimally invasive lung cancer surgery using video-assisted thoracic surgery (VATS) has increased dramatically over the past decade, yet recent studies have suggested that the lymph node evaluation during VATS lobectomy is inadequate. We hypothesized that the minimally invasive approach to lobectomy for stage I lung cancer resulted in a longitudinal outcome that was not inferior to thoracotomy. Patients and Methods Patients > 65 years of age who had undergone lobectomy for stage I lung cancer between 2002 and 2013 were analyzed within the Society of Thoracic Surgeons General Thoracic Surgery Database, which had been linked to Medicare data, as part of a retrospective-cohort, noninferiority study. Results A total of 10,597 patients with clinical stage I lung cancer who underwent lobectomy were evaluated (4,448 patients underwent thoracotomy, and 6,149 underwent VATS). VATS patients had a more favorable distribution of all health-related variables, including pulmonary function (59% of VATS patients had intact spirometry v 51% of thoracotomy patients; P < .001). Cox proportional hazards models were performed over two eras to account for an evolving practice standard. The mortality risk associated with the VATS approach was not greater than thoracotomy in either the earlier era (2002 to 2008; hazard ratio, 0.97; 95% CI, 0.87 to 1.09; P = .62) or the more recent era (2009 to 2013; hazard ratio, 0.84; 95% CI, 0.75 to 0.93; P < .001). Kaplan-Meier survival estimates of 2,901 propensity-matched VATS-thoracotomy pairs demonstrated that the 4-year survival associated with VATS (68.6%) was modestly superior to thoracotomy (64.8%; P = .003). The analyses detailed above were replicated in a separate cohort of pathologic stage I patients with similar findings. Conclusion The long-term efficacy of lobectomy for stage I lung cancer performed using the VATS approach by board-certified thoracic surgeons does not seem to be inferior to that of thoracotomy.

Indexed as

AgedCohort StudiesFemaleHumansKaplan-Meier EstimateLongitudinal StudiesLung NeoplasmsMaleMinimally Invasive Surgical ProceduresNeoplasm StagingPropensity ScoreProportional Hazards ModelsThoracotomyTreatment Outcome

Identifiers

PMID29791289
OpenAlexW2804475709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.